Compassionate use of Jusvinza in the treatment of a patient with severe Leptospirosis associated with the Jarisch Herxeimer reaction

Introduction: Approximately 10% of human leptospirosis cases progress to severe forms, among which Weil syndrome stands out. This condition can be aggravated by complications associated with antibiotics, such as the Jarisch Herxeimer reaction (JHR) that intensifies inflammation. Treatment with Jusvinza may be an option for these states mediated by hyperinflammation. Objective: To describe the clinical evolution of a patient with leptospirosis and Weil's syndrome who developed the JHR and was treated with Jusvinza. Case Report: 50-year-old male patient was diagnosed with Leptospirosis, which progressed to a serious condition and Weil syndrome and received treatment with ceftriaxone, as result he developed JHR, which led to the use of mechanical ventilation and the compassionate use of Jusvinza. The clinical, radiological, and humoral improvement was evident 48 hours after starting treatment. Conclusions: Treatment with Jusvinza induced a decrease in several biomarkers of systemic inflammation and contributed to the patient's recovery. These results indicate that Jusvinza may be an effective option for the treatment of severe forms of Leptospirosis and its complications, associated with hyperinflammation.